# US 2020/0368373 A1 · Optical imaging agents targeting inflammation

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0368373 A1
- Document ID: US20200368373A1
- Status: Published application
- Kind: A1
- Application number: 16/968,272
- Filed: 2019-02-21
- Published: 2020-11-26
- Earliest claimed: 2018-02-21
- Applicants: Sorbonne Universite; Institut National De La Sante Et De La Researche Medicale; Ecole National Superieure De Chimie De Paris; Centre National De La Recherce Scientifique; Universite De Paris
- Inventors: Yongmin ZHANG; Michel BESSODES; Johanne SEGUIN; Nathalie MIGNET; Daniel SCHERMAN
- Web page: https://patentgrep.com/patent/US20200368373A1

## CPC

- A61K 49/0032: {Methine dyes, e.g. cyanine dyes}
- A61K 49/0091: {Microparticle, microcapsule, microbubble, microsphere, microbead, i.e. having a size or diameter higher or equal to 1 micrometer}
- A61K 49/0052: {Small organic molecules (oligomers, polymers, dendrimers A61K49/0054)}
- A61K 49/0054: {Macromolecular compounds, i.e. oligomers, polymers, dendrimers}
- A61K 49/0056: {Peptides, proteins, polyamino acids}
- A61K 49/0093: {Nanoparticle, nanocapsule, nanobubble, nanosphere, nanobead, i.e. having a size or diameter smaller than 1 micrometer, e.g. polymeric nanoparticle}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention relates to an optical imaging agent of formula (SIGNAL)n-SUPPORT-(L-BIOVECTOR)m, wherein: SUPPORT represents a physiologically acceptable chemical or biological substrate, with a particle size of between 1 and 100 nm, SIGNAL is a fluorophore, L is a linker of formula —C(X)—R1—Y—, with X being O, NH or S R1 being a (C1-C6)alkyl group, optionally R1 being a (C1-C6)alkyl group, optionally interrupted by 1 to 3 groups selected from —O—, —NH—, —C(O)—, —NHC(O)—, —(O)CNH—, —C(O)NH—N═C—, —N═C—, and (I), Y being NH or a —(O)CNH— group, and BIOVECTOR is a carbohydrate targeting markers of inflammation, advantageously selected from the group consisting of mannose, sialyl LewisX and derivatives thereof, n is greater than or equal to 0.5 and is less than 2, m is between 0 and 30, preferably between 1 and 30, more preferably between 5 and 20, diagnostic compositions comprising same and use thereof as a diagnostic agent (in vivo or ex vivo), or as contrast agent for image-guided surgery.

## Claims

### Claim 1

Optical imaging agent of formula (SIGNAL)n-SUPPORT-(L-BIOVECTOR)m, wherein:
SUPPORT represents a physiologically acceptable chemical or biological substrate, with a particle size of between 1 and 100 nm,
SIGNAL is a fluorophore,
L is a linker of formula —C(X)—R1—Y—, with
X being O, NH or S,
R1 being a (C1-C6)alkyl group, preferably a (C3-C5)alkyl group, optionally interrupted by 1 to 3 groups selected from —O—, —NH—, —C(O)—, —NHC(O)—, —(O)CNH—, —C(O)—NH—N═C—, —N═C—, and
Y being NH or —(O)CNH—, and
BIOVECTOR is a carbohydrate able to target markers of inflammation,
n is greater than or equal to 0.5 and is less than 2,
m is between 1 and 30,
or a pharmaceutically acceptable salt, solvate or hydrate thereof.

### Claim 2 (depends on 1)

The optical imaging agent of claim 1, wherein SUPPORT is a protein.

### Claim 3 (depends on 1)

The optical imaging agent of claim 1, wherein SUPPORT is an albumin with a particle size of between 1 and 100 nm.

### Claim 4 (depends on 1)

The optical imaging agent of claim 1, wherein SIGNAL is of formula (I):
wherein
q is 0 or 1,
r is 0 or 1,
Rb1 and Rb2 are H or a C1-C4 group, or are bridged to form a —CH2—CH2—CH2— alkylene group (only when q and r represent 1),
Ra1 and Ra2 are identical or different and are independently a (C1-C6)alkyl group, optionally substituted by a SO3− group, a SO3K group, a SO3Na group, or a COOH group, provided that not more than one of Ra1 and Ra2 is substituted by a SO3− group,
Ring A represents a C5-C6 monocyclic aryl or heteroaryl group or a C8-C12 fused bicyclic aryl or heteroaryl group,
provided that the compound of formula (I) comprises at least one SO3− or SO3Na group, but not more than one SO3− group, and that when the compound of formula (I) has an overall positive electric charge, it is provided as a salt, in particular a halogenide salt such as a chloride Cl− salt.

### Claim 5 (depends on 1)

The optical imaging agent of claim 1, wherein X is NH and R1 is a (C1-C6) alkyl, optionally interrupted by a
group.

### Claim 6 (depends on 1)

The optical imaging agent of claim 1, wherein BIOVECTOR is of formula (II):
wherein R2 represents a (C1-C6)alkyl group, and X′ represents a heteroatom such as O, S or NH, or a compound of formula (III) or (IV)
wherein R is R2—X′, with R2 being a (C1-C6)alkyl group and X′ being a heteroatom such as O, S or NH, and Rs is H, SO3K or SO3Na.

### Claim 7 (depends on 1)

The optical imaging agent of claim 1, wherein BIOVECTOR is of formula (V), (VI) or (VII):
wherein R is R2—X′, with R2 being a (C1-C6)alkyl group and X′ being a heteroatom such as O, S or NH.

### Claim 8 (depends on 1)

A diagnostic composition comprising at least one optical imaging agent according to claim 1, a pharmaceutically acceptable salt, solvate or hydrate thereof, and at least one pharmaceutically acceptable excipient.

### Claim 9 (depends on 1)

An in vivo diagnostic method comprising administering to a patient in need thereof an effective amount of the optical imaging agent according to claim 1.

### Claim 10 (depends on 9)

The in vivo diagnostic method according to claim 9, comprising diagnosing diseases or conditions associated with inflammation.

### Claim 11 (depends on 10)

The in vivo diagnostic method according to claim 10, wherein the disease or condition associated with inflammation is selected from stroke, renal failure or cancer.

### Claim 12 (depends on 9)

The in vivo diagnostic method according to claim 9, wherein said method is applied to surgical resection of tumours in the patient and comprises the following further successive steps:
resecting the tumoral tissue identified prior to surgery in an area of interest;
imaging the area of interest of the patient, to whom the effective amount of the optical imaging agent has been administered prior to surgery or during surgery, using an optical imaging device, so as to identify remaining tumoral tissues;
when light signals are observed in the area of interest defining remaining tumoral tissues, proceeding with the resection of the identified remaining tumoral tissues; when no light signal is observed in the area of interest, not proceeding with any further resection in the area of interest.

### Claim 13 (depends on 1)

A method of imaging a biological tissue ex vivo, wherein said biological tissue comprises the optical imaging agent according to claim 1, the method comprising applying optical or fluorescence imaging to said tissue.

### Claim 14 (depends on 13)

The method of claim 13, wherein the biological tissue is a biopsy sample.

### Claim 15 (depends on 13)

The method of claim 13, further comprising a step of diagnosing a disease or condition associated with inflammation from said optical or fluorescence imaging.

### Claim 16 (depends on 1)

The optical imaging agent of claim 1, wherein SUPPORT is a human serum albumin with a particle size of between 1 and 100 nm.

### Claim 17 (depends on 4)

The optical imaging agent of claim 4, wherein Ring A represents a C5-C6 monocyclic aryl group or a C8-C12 fused bicyclic aryl group, such as a phenyl or naphthyl group.

### Claim 18 (depends on 4)

The optical imaging agent of claim 4, wherein Ring A is substituted by one SO3− or SO3Na group, provided that not more than one of Ra1 and Ra2 is substituted by a SO3− group.

### Claim 19 (depends on 6)

The optical imaging agent of claim 6, wherein R2 represents a (C1-C4)alkyl group and X′ represents NH.
